An exciting new era in cancer research is emerging, called precision oncology. It builds on decades of research establishing that cancers start with glitches in the genome, the cell’s instruction book.
To explain the many challenges involved in turning scientific discoveries into treatments and cures, I often say, “Research is not a 100-yard dash, it’s a marathon.” Perhaps there is no better example of this than cystic fibrosis (CF).
In these times of tight budgets and rapidly evolving science, we must consider new ways to invest biomedical research dollars to achieve maximum impact—to turn scientific discoveries into better health as swiftly as possible. We do this by thinking strategically about the areas of research that we support, as well as the process by which we fund that research.
I’d like you to meet Melissa Young, a third-year graduate student in the College of Pharmacy, University of Georgia, Athens. Young, who is doing research in the lab of James Franklin, says her scientific goal is to help build the scientific case that oxidative stress plays a key role in Alzheimer’s disease.
Channeling Humphrey Bogart’s hard-boiled approach to detective work, the protagonist of this video is tracking down #metabolites — molecules involved in biological mysteries with more twists and turns than “The Maltese Falcon.”
This longtime University of Chicago researcher was a pioneer in the truest sense of the word. Her discoveries about cancer genetics dramatically changed our understanding of the disease and opened the door to the development of personalized medicines for cancer.